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Survival of children with relapsed acute lymphoblastic leukemia ispoor, and understanding mechanisms underlying resistance isessential to developing new therapy. Relapse-specific heterozygous
deletions in MSH6, a crucial part of DNA mismatch repair, are frequent-
ly detected. Our aim was to determine whether MSH6 deletion results
in a hypermutator phenotype associated with generation of secondary
mutations involved in drug resistance, or if it leads to a failure to initiate
apoptosis directly in response to chemotherapeutic agents. We knocked
down MSH6 in mismatch repair proficient cell lines (697 and UOCB1)
and showed significant increases in IC50s to 6-thioguanine and 6-mer-
captopurine (697: 26- and 9-fold; UOCB1: 5- and 8-fold) in vitro, as well
as increased resistance to 6-mercaptopurine treatment in vivo. No shift in
IC50 was observed in deficient cells (Reh and RS4;11). 697 MSH6 knock-
down resulted in increased DNA thioguanine nucleotide levels com-
pared to non-targeted cells (3070 vs. 1722 fmol/μg DNA) with no differ-
ence observed in mismatch repair deficient cells. Loss of MSH6 did not
give rise to microsatellite instability in cell lines or clinical samples, nor
did it significantly increase mutation rate, but rather resulted in a defect
in cell cycle arrest upon thiopurine exposure. MSH6 knockdown cells
showed minimal activation of checkpoint regulator CHK1, γH2AX
(DNA damage marker) and p53 levels upon treatment with thiopurines,
consistent with intrinsic chemoresistance due to failure to recognize
thioguanine nucleotide mismatching and initiate mismatch repair.
Aberrant MSH6 adds to the list of alterations/mutations associated with
acquired resistance to purine analogs emphasizing the importance of
thiopurine therapy.
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ABSTRACT
Introduction
Relapsed B-precursor acute lymphoblastic leukemia (B-ALL) is a leading cause of
cancer mortality amongst children. Development of chemoresistance is a crucial
factor contributing to relapse, therefore understanding the biological mechanisms
underlying this resistance is imperative for discovering innovative treatment strate-
gies.1 Recent work has begun to highlight the direct role of relapse
specific/enriched genetic alterations in the emergence of clones that have gained a
selective advantage under the pressure of specific chemotherapeutics, such as
NT5C2, TBL1XR1, PRPS1, and CREBBP.1-5 Many of these mutations cause resist-
ance specifically to thiopurines, which are the backbone of maintenance therapy
and have proven vital for achieving cures.6 Our analysis of
copy number alterations (CNAs) in diagnosis/relapse pairs
revealed a relapse specific hemizygous deletion on chro-
mosome 2p16.3 involving MSH6 in 4-10% of patients.7,8 
MutS homolog 6 (MSH6) is a major component of the
mismatch repair (MMR) system, which is a highly con-
served biological process that recognizes and repairs
errors in nascent DNA strands during replication to main-
tain genomic integrity. Initial recognition of replicative
errors is carried out by protein heterodimers consisting of
either MSH6 and MSH2 (hMutSa), or MSH3 and MSH2
(hMutSβ). Upon recognition of a mismatch, hMutSa
recruits MutLa (MLH1-PMS2) which engages down-
stream proteins and enzymes involved in DNA repair.9,10 
Constitutional defects in MMR, including monoallelic
mutations in Lynch syndrome and biallelic loss in consti-
tutional mismatch repair deficiency (CMMRD), are
strongly linked to carcinogenesis, where loss of MMR
functionality causes increased mutability and predisposi-
tion to malignancy.11-15 Previous work has linked defects
in MMR to drug resistance, including thiopurines, in var-
ious cancers.16-19 However, it is uncertain if resistance in
MMR defective clones occurs through the acquisition of
secondary mutations as a consequence of mutagenic ther-
apy, or the outgrowth of clones that have intrinsic drug
resistance. Our lab previously demonstrated that lower
expression of MSH6 in patient samples was associated
with increased ex vivo resistance to 6-mercaptopurine and
prednisone,7 highlighting the clinical importance of under-
standing the role of this genetic alteration in B-ALL.
The mechanism of action of thiopurines is based upon
the insertion of a false nucleotide, namely a thioguanine
(TGN), into DNA that when thiomethylated pairs with a
thymine instead of a cytosine.18 Cytotoxicity is thought to
be dependent on the MMR machinery recognizing the
mismatch and attempting to match the TGN on the
parental strand with an appropriate base on the daughter
strand.19,20 Whether the DNA damage induced by the
repetitive, futile cycles of DNA excision and repair, or
simply the recognition of mismatches by hMutSa is
enough to initiate a signaling cascade culminating in cell
cycle arrest and apoptosis is not entirely understood.
We sought to delineate whether reduced expression of
MSH6 could give rise to chemoresistance in B-precursor
ALL and elucidate the mechanism responsible for the
resistance. Our data here support the view that reduced
MSH6 directly results in an increased tolerance to incor-
porated TGN and subsequent mismatches through a fail-
ure to initiate MMR, thus allowing cells to proliferate and
survive under thiopurine treatment both in vitro and in
vivo. We demonstrate that ALL cell lines with a functional
MMR trigger a CHK1-mediated cell cycle arrest in
response to thiopurines that is followed by DNA damage
and apoptosis. In contrast, upon reduction of MSH6, the
MMR signaling cascade is not fully activated and cells do
not undergo apoptosis. 
Methods
Cells and reagents 
The B-lineage leukemia cell lines RS4;11 (ATCC, Manassas, VA,
USA), Reh (ATCC), 697 (DSMZ, Braunschweig, Germany), and
UOCB1 (a kind gift from Dr. Terzah Horton at Texas Children’s
Cancer Center/Baylor College of Medicine) were grown in
RPMI1640 medium. HEK293T (ATCC) cells were grown in
DMEM medium. All media were supplemented with 10% FBS,
1% penicillin/streptomycin under 5% CO2 at 37°C. 
Drug preparation, viral preparation, immunoblotting,
apoptosis assays, and cell cycle 
Standard protocols were followed and have been previously
described.3,21 More detailed information is provided in the Online
Supplementary Appendix.  
Patients’ samples
Cryopreserved pediatric B-ALL specimens were obtained from
the Children's Oncology Group (COG) ALL cell bank. All patients
were treated on COG protocols for newly diagnosed ALL. All sub-
jects provided consent for banking and future research use of these
specimens in accordance with the regulations of the institutional
review boards of all participating institutions.
Microsatellite instability analysis 
Microsatellite instability (MSI) analysis was performed using
MSI Analysis System, v.1.2 (Promega, Madison, WI, USA) follow-
ing the manufacturer’s protocol. Detailed information is provided
in the Online Supplementary Appendix. 
Measurement of mutation rate
Spontaneous mutation rate was measured using a flow cytom-
etry assay previously described by Araten et al.22 that detects the
presence of numerous glycosylphosphatidylinositol-linked (GPI)
membrane proteins (see Online Supplementary Appendix). Briefly,
GPI(+) isolated clones from the NT and MSH6-KD cell lines were
expanded either untreated or treated with 6-TG (0.040 μg/mL and
0.100 μg/mL, respectively, based on IC50 values determined for
clones). Cells were then stained for GPI-dependent markers
including FLAER-Alexa 488 (Pinewood), CD48, CD52, and CD59
(Serotec),23 and analyzed by flow cytometry. The mutant frequen-
cy (f) was calculated as the number of GPI(-) events divided by the
total number of live events, and mutation rate (μ) was calculated
as f divided by cell divisions.22 
Thioguanine quantification assay
Cells were treated with 6-thioguanine (6TG) and collected every
day for four days. DNA was extracted using Puregene Core Kit A
(QIAGEN). DNA TGN levels were measured using liquid chro-
matography-tandem mass spectrometry as described previously.24 
In vivo mouse model of chemoresistance
All experiments were conducted on protocols approved by
the Institutional Animal Care and Use Committee and
Institutional Review Board of the Children's Hospital of
Philadelphia. Briefly, 1 million UOCB1 NT GFP-CBG or MSH6
shRNA1 GFP-CBR cells were injected into NSG mice via tail vein
on day 0 (total 20 mice; 10 per cell line). On day 6 leukemic bur-
den was confirmed via bioluminescence imaging (BLI) (IVIS
Spectrum imaging system, Perkin Elmer) and animals were ran-
domized to treatment groups [PBS vehicle or Purixan (50 mg/kg)
diluted in PBS]. Mice were treated on day 7 by gavage (0.2
mL/mouse). For BLI, 3 mg of luciferin was injected intraperi-
toneally and mice were imaged ten minutes post injection.
Quantification of total flux was determined by analyzing the BLI
images using Living Image Software (Perkin Elmer) (see Online
Supplementary Appendix). 
Statistical analysis
Statistical significance was calculated using unpaired t-test for
IC50s, paired t-test for mutation rates, one-way ANOVA for cell
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Figure 1. Knockdown of MSH6 in mismatch repair (MMR) proficient cells lead to decreased sensitivity to thiopurines. (A-C, left) Western blot analysis of whole cell
lysates from 697 (A), UOCB1 (B), and Reh and RS4;11 (C). (A-C, right) Apoptotic cells measured by Annexin V and 7AAD staining followed by flow cytometry after 5
days of treatment. Graphs represent 3 experiments each performed with duplicates. Bars indicate mean+Standard Deviation.
A
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cycle analysis, and two-way ANOVA for mutation rates with and
without treatment as well as in vivo studies. 
Results
Previously we noted relapse-specific heterozygous dele-
tions in MSH6 in 4 out of 76 patients that were near iden-
tical and deleted MSH6 only for 3 patients while one har-
bored a larger deletion involving more genes within the
region (Online Supplementary Figure S1). To begin to eluci-
date the impact of MSH6 deletion on the development of
relapsed disease, we knocked down expression of MSH6
using shRNA in 697 cells, a B-ALL cell line that expresses
all four MMR proteins (Figure 1A) and is MMR profi-
cient,25 and tested for changes in chemosensitivity. We
observed approximately 80-90% (shRNA1) and 50-60%
(shRNA2) knockdown of MSH6 expression, as well as
decreased expression of MSH2, compared to non-target-
ing (NT) control cells (Figure 1A), which is consistent with
literature on the loss of protein stability of MSH2 and
MSH6 when not dimerized.17,26 Knockdown of MSH6
with both shRNA1 and shRNA2 leads to a significant
decrease in apoptotic cells when treated with thiopurines
for five days (Figure 1A). A 26-fold increase in IC50 with
6-TG (NT: 0.027 vs. shRNA1: 0.716 μg/mL; P=0.007) and
8.5-fold increase for 6-MP (NT: 0.340 vs. shRNA1: 2.89
μg/mL; P=0.006) was observed for shRNA1 (Online
Supplementary Figure S2). A 1.7-fold (NT: 0.015 vs.
shRNA2: 0.025 μg/mL; P=0.015) and a 2.6-fold (NT: 0.143
vs. shRNA2: 0.373 μg/mL; P=0.032) increase in IC50 for 6-
TG and 6-MP, respectively, were observed for shRNA2
cells compared to NT cells (Online Supplementary Figure
S2). However, no significant differences were observed
when cells were treated with prednisolone (Pred), doxoru-
bicin (Doxo), cytarabine (Ara-c), or methotrexate (MTX)
(Online Supplementary Figure S3A). Interestingly, we found
that knockdown of MSH6 also resulted in decreased sen-
sitivity to temozolomide (TMZ), an alkylating agent used
to treat glioblastomas, as reported previously (Online
Supplementary Figure S3B).27,28 
To further support the role of MSH6 in chemoresis-
tance, we knocked down expression in UOCB1 cells,
another B-ALL cell line that expresses all four MMR pro-
teins (Figure 1B). Similar to the effect observed in 697 cells,
depletion of MSH6 with either shRNA significantly
reduced the induction of apoptosis upon treatment with
thiopurines (Figure 1B) [fold increase in IC50 as compared
to NT with 6TG: 4.8 for shRNA1 (P=0.007) and 3 for
shRNA2 (P<0.001); 6MP: 8.3 for shRNA1 (P<0.001) and
9.2 shRNA2 (P<0.001)] (Online Supplementary Figure S4).
Additionally, a similar impact on TMZ resistance was
observed with UOCB1 MSH6 shRNA1 expressing cells
compared to NT control cells, although shRNA2 did not
show the same effect, possibly due to less depletion by
shRNA2 (Online Supplementary Figure S3B).
To determine the specificity of the phenotype
observed for MSH6 depletion versus defects in other
MMR proteins, we assessed the effect of MSH6 knock-
down in MMR deficient B-ALL cell lines Reh and
RS4;11.25,29 Both Reh and RS4;11 have minimal to no
expression of MLH1 and PMS2 (Figure 1C). Knockdown
of MSH6 expression had no effect on the sensitivity of
either Reh or RS4;11 to 6-TG or 6-MP (Figure 1C and
Online Supplementary Figure S5). 
To begin to elucidate the mechanism of resistance, we
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Figure 2. Knockdown of MSH6 leads to increased
tolerance of incorporated thioguanine (TGN). (A and
B) TGN incorporation into DNA was measured over
time after treatment with 0.1 μg/mL of 6-thiogua-
nine (6-TG) in 697 (A) and Reh (B) cells using liquid
chromatography-tandem mass spectrometry. A rep-
resentative graph from 3 independent experiments
is shown. (C) Combined ratio of TGN fmole/μg of DNA
in MSH6 shRNA1 knockdown (KD) cells compared to
non-targeting (NT) cells from 3 experiments. Bars
indicate mean+Standard Deviation.
A B
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measured the level of TGN incorporation into DNA upon
treatment with 6-TG. 697 MSH6 shRNA1 cells accumulat-
ed more TGN/μg DNA over time than NT cells (NT 1722
and KD 3070 fmol/μg DNA) (Figure 2A and C). In con-
trast, no difference in TGN levels was observed in Reh
cells (Figure 2B and C). Additionally, Reh cells had approx-
imately 10-fold higher TGN levels compared to 697 cells
(Figure 2A and B), highlighting the difference between
MMR deficient and proficient cells in their ability to
respond to and survive thiopurine exposure. Thus, MMR
proficient cells with high TGN succumb to the damage
and therefore display less TGN/μg DNA over time, mean-
while deficient cells tolerate higher levels of TGN. 
We next tested whether or not a change occurs in cell
cycle progression upon treatment. 697 NT cells slowed
their growth and had a significantly higher proportion of
cells in S phase and less cells in G1 beginning at 96 hours
(h) (6-TG, P=0.014; 6-MP, P=0.051) and progressing
N.A. Evensen et al.
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Figure 3. Thiopurine treatment resulted in an S phase arrest, which was abrogated upon knockdown of MSH6. 697 (A) and UOCB1 (B) NT and MSH6 shRNA1 and
2 expressing cells were treated with indicated drug for 5 days. Cells were fixed with 70% ethanol, treated with RNAse, and then stained with propidium iodide. DNA
content was analyzed by flow cytometry. Representative images from 3 individual experiments are shown. A one-way ANOVA was performed to determine statistical
significance of the increase in % of cells in S phase at each time point.
A
B
through 120 h of thiopurine treatment (6-TG, P=0.013; 6-
MP, P=0.001) compared to the MSH6 shRNA lines by one-
way ANOVA (Figure 3A and Online Supplementary Figure
S6A). MSH6 shRNA1 cells had only a modest decrease in
growth with no clear S phase arrest (6-TG, P=0.011, and
6-MP, P=0.001, for percent of cells in S phase compared to
NT at 120 h using Tukey’s multiple comparison test), even
at higher concentrations of 6-TG (Figure 3A and Online
Supplementary Figure S6A and B). MSH6 shRNA2 cells had
a more moderate accumulation of cells in S phase and
drop of cells in G1 (Figure 3B and Online Supplementary
Figure S6A), which is consistent with the modest levels of
knockdown and apoptosis. Similar trends were observed
with UOCB1 cells (6-TG, P=0.31; and 6-MP, P=0.34 at 120
h) (Figure 3B). This more moderate effect observed with
the UOCB1 cells is consistent with the degree of impact
MSH6 knockdown had on chemoresistance compared to
the 697 cells. Neither NT nor MSH6 shRNA1 Reh cells
showed alterations in cell cycle upon exposure (Online
Supplementary Figure S6B). 
To gain a more complete understanding of the mecha-
nism leading to apoptosis following TGN incorporation,
we analyzed downstream pathways in 697 NT and MSH6
shRNA1 cells after treatment with 6-TG. Based on the
observed S phase arrest and previous research demonstrat-
ing activation of the ataxia telangiectasia and Rad3-related
(ATR)-Chk1 pathway downstream of MMR,30,31 we first
assessed the level of activation of Chk1 by probing for
phosphorylation of serine 317 (pChk1). 697 NT cells had
a low level of pChk1 at 48 h with a significant increase
through 96 h of exposure. 697 MSH6 shRNA1 cells had
minimal to low levels of pChk1 at 72 h with minimal
increase over time (Figure 4A). The 697 cells expressing
shRNA2 had a similar pattern but slightly lower levels of
pChk1 compared to NT cells, which is consistent with the
cell cycle data. We next assessed the level of phosphory-
lated H2AX (γH2AX), a marker of DNA damage that is
phosphorylated downstream of the ATR/ATM pathways
following drug treatment,32 as well as levels of the apopto-
sis marker p53. There was a very modest level of γH2AX
starting at 72 h that increased to a higher level at 96 h after
treatment in 697 NT cells compared to very modest levels
in the MSH6 shRNA1-2 cells (Figure 4A), suggesting that
the functional MMR system in the NT cells was attempt-
ing to repair the DNA, leading to nicks. Additionally, the
levels of phosphorylated and total p53 were higher in NT
cells at 72 and 96 h compared to MSH6 shRNA1-2 cells
(Figure 4A) and the shRNA2 cells had higher levels than
the shRNA1 cells. Similar results were found in UOCB1
cells (Figure 4B). 
We next examined the impact of MSH6 knockdown on
mutation rate by performing two assays that measure
genomic instability and mutation burden. Microsatellite
instability (MSI) is a marker for genomic instability and
has been observed in cases where expression of MLH1 or
MSH2 is lost.25,33 We investigated MSI on 2 patient sample
pairs that we previously found to have deletions of MSH6
at relapse, as well as on 697 NT and MSH6 shRNA1 cells
treated with 6-TG for 120 h. No MSI was observed in the
patient samples comparing diagnosis to relapse or in the
697 cells comparing either untreated to 6-TG treated or
NT to MSH6 shRNA1 cells (Figure 5A). These data are
consistent with previous literature that found alterations
in MSH6 expression alone do not lead to high MSI.34 To
investigate the effect of MSH6 disruption on the rate of
spontaneous mutations in PIG-A, which is required for
expression of GPI, we used a flow cytometry-based assay
that measures surface expression of several GPI-depen-
dent markers (CD48, CD52, and CD59).22,35 Although
there was a trend to suggest that 697 MSH6 shRNA1 cells
had a slightly higher mutation rate, statistical significance
was not achieved (Figure 5B). Furthermore, treatment of
the clones from each cell line with 6-TG did not lead to an
increased mutation rate (Figure 5B).
To investigate the clinical relevance of reduced MSH6
expression and drug resistance, we utilized an in vivo
mouse model. We injected mice with either UOCB1 NT
or UOCB1 MSH6 shRNA1 cell lines (knockdown con-
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Figure 4. Thiopurine treatment leads to activation of cell cycle regulator Chk1 and DNA repair that ultimately resulted in DNA damage and cell death. Western
blot analysis of whole cell lysates from 697 (A) and UOCB1 (B) non-targeting (NT), MSH6 shRNA1, and shRNA2 cells after treatment with 6-thioguanine  (0.1 μg/mL,
and 0.025 μg/mL, respectively). (C) Untreated cells; numbers are hours after treatment. Blots were probed for Chk1 activation, γH2AX for DNA damage, and apop-
tosis marker p53. Total Chk1, actin, and total H2AX were used as loading controls. Images are representative of 3 individual experiments.
A B
firmed day of injection; Figure 6C) and, following confir-
mation of leukemic burden on day 6, the mice were treat-
ed with PBS (control) or purixan (an oral suspension form
of 6-MP). Following the 10-day course of purixan treat-
ment, the leukemic burden was significantly diminished
in the mice harboring NT cells compared to that observed
in the NT PBS treated mice (P=0.0001), suggesting that
these cells were unable to survive and expand under the
selective pressure of the purixan (Figure 6A and B). In con-
trast, the MSH6 shRNA1 mice treated with purixan were
not significantly different from the NT PBS group
(P=0.828). Although purixan also had a statistically signif-
icant impact on MSH6 shRNA1 cells compared to MSH6
shRNA1 PBS control (P=0.0005), these cells were able to
continue proliferating under the selective pressure, unlike
the NT cells (Figure 6A and B). Finally, a comparison
between PBS MSH6 shRNA1 and PBS control NT cells at
day 17 showed that MSH6 depleted cells also had a
growth advantage in vivo (P<0.0001).
Discussion
In recent years, there has been an abundance of evi-
dence demonstrating the outgrowth of clones at relapse in
ALL that are associated with unique or enriched relapse
specific mutations that confer drug resistance. Some of the
most common relapse specific mutations found thus far
occur in NT5C2 and PRPS1 and lead to the outgrowth of
thiopurine resistant clones.2,4 Our data presented here
demonstrate that reduction of MSH6 in ALL also leads to
decreased sensitivity to purine analogs due to a failure to
initiate the apoptotic cascade directly in response to
nucleotide mismatches. Even with only 50-60% reduced
expression, which potentially mimics levels in patients
with heterozygous loss, we demonstrate a significant
decrease in sensitivity to thiopurines. Our data are consis-
tent with the recent work of Diouf et al. who showed that
lower levels of MSH2 in cell lines were associated with
resistance to 6-TG and 6-MP. They found 11% of ALL
samples showed decreased protein levels of MSH2
through copy number loss of genes controlling MSH2
degradation.17 Thus defects in MMR, including heterozy-
gous deletion of MSH6, can be added to the list of genetic
alterations that result in the development of resistance to
purine analogs, the foundation of maintenance therapy.
The variety of mutations that lead to selective outgrowth
of such clones in a substantial number of patients under-
scores the selective pressure of thiopurines on tumor cells. 
The outgrowth of MSH6 deleted/mutated clones not
found at diagnosis has been observed at relapse in malig-
nant gliomas following treatment with temozolo-
N.A. Evensen et al.
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Figure 5. Knockdown of MSH6 did not lead to a mutator phenotype or increased mutation rate. (A) Microsatellite instability (MSI) was measured in diagnosis/relapse
pairs that had relapse specific, heterozygous MSH6 deletions and in 697 non-targeting (NT) and MSH6 shRNA1 cells left untreated or treated with 0.05 μg/mL of
6-thioguanine (6-TG) for 5 days. (B) Mutation rate in the PIC-A gene was measured in 697 NT and MSH6 shRNA1 clones that were expanded for 2-3 weeks with or
without 6-TG. The cells were analyzed for loss of GPI-dependent cell surface markers, including FLAER, CD48, CD52, and CD59 using flow cytometry. (Left) Individual
mutation rates/cell divisions for each clone; the line represents mean+Standard Deviation. (Right) Mutation rates/cell divisions for three clones with and without 6-
TG treatment. 
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mide,28,36,37 which produces DNA O6-methyguanine, a
lesion structurally similar to 6-TG.38 Our data demonstrat-
ing decreased sensitivity of MSH6 knockdown cells to
temozolomide support the hypothesis that MMR defi-
cient clones gain an advantage under this selective pres-
sure leading to resistant recurrences.27,39 The difference in
TMZ sensitivity between the two UOCB1 shRNA knock-
down cell lines could be due to the interplay between
MSH6 and SETD2 protein levels since UOCB1 cells have
a copy number loss of SETD2 (NA Evensen et al., 2018,
unpublished data) and there is a greater reduction of MSH6
with shRNA1 compared to shRNA2. SETD2, the gene that
codes for the methyltransferase responsible for the
trimethylation of H3K36 that serves as the docking site for
MSH6,40 is among the epigenetic regulators commonly
found mutated in relapse patients.41 Ongoing studies in our
lab are focused on identifying the relationship of epigenet-
ic readers, writers, and erasers, such as SETD2, MSH6,
and WHSC1 in chemoresistance. 
Mechanistically, our in vitro and in vivo data support the
hypothesis that the delayed cytotoxic response to thiop-
urines is due to the MMR system recognizing a mismatch
and initiating futile, damaging DNA repair that ultimately
leads to apoptosis.20,42,43 This pathway is not fully activated
in cells with reduced MSH6 because the mismatch goes
undetected, allowing these cells to tolerate excess TGN
mismatches and, ultimately, to continue to survive and
proliferate while under treatment. Our data provide evi-
dence that, upon recognition of mismatches, NT cells
slow their progression through S phase by activating
Chk1 as they begin to repair their DNA. Due to the mis-
match being on the daughter strand, the excision/repair
process is unsuccessful, and over time nicks build up in the
DNA, demonstrated by increased levels of γH2AX.
Eventually, the damage becomes overwhelming and cells
initiate apoptosis, as shown by increased p53. MSH6
shRNA1 cells exhibited minimal to no change in cell cycle,
activation of Chk1, or increased γH2AX and p53. The
moderate changes observed with the MSH6 shRNA2 cells
highlight the idea that even a more modest reduction in
MSH6 expression could lead to subtle changes that have a
significant impact on chemoresistance. The MMR defi-
cient Reh cells also had no alteration in their cell cycle,
suggesting that recognition of mismatches by MutSa is
not sufficient for full activation of this cascade, but rather
damage induced by the repair, which is orchestrated by
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Figure 6. Knockdown of MSH6 leads to decreased sensitivity to purixan in vivo. (A) Bioluminescence imaging (BLI) of mice injected with UOCB1 non-targeting (NT)
or MSH6 shRNA1 cells. Six days after injection mice were imaged and then randomized to treatment. Treatment was started on day 7 and images were taken again
on days 13 and 17. C: PBS control treatment; T: purixan treatment. (B) Quantification of total flux was determined by analyzing the BLI images using Living Image
software. (C) Western blot to confirm knockdown of MSH6 in cells used to inject mice. Actin was used as loading control.
A
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MutLa, is what initiates apoptosis. Our data demonstrat-
ing the involvement of the ATR-Chk1-H2AX signaling
cascade is supported by the work of Eich et al. which
demonstrated activation of this pathway upon treatment
with temozolomide.32 Interestingly, understanding how
MMR deficient cells respond to thiopurines in terms of
TGN incorporation could prove essential given the emerg-
ing idea of measuring these parameters in patients on
maintenance therapy.44 
The data presented here do not support the hypothesis
of increased mutation burden, genomic instability, or MSI
when MSH6 is reduced. Our inability to demonstrate
MSI-high, which is considered a standard method for clin-
ical testing of MMR deficiencies in tumors,45 in MSH6
depleted cell lines and clinical samples is consistent with
the lack of MSI in glioma samples with MSH6 deletions or
mutations.46,47 Haploinsufficiency of MSH6 or compensa-
tion by MSH2/MSH3 may account for this observation.25,48
In addition, ALL clonal evolution from diagnosis to relapse
is not associated with increased mutation burden support-
ing our mutation rate analysis, although Ma et al. reported
a subset of hypermutated relapse cases.49 Of these, one
had a bialleic mutation of PMS2, another had multiple
damaging MSH6mutations as well as an MLH1 splice site
mutation, while the others harbored no MMR muta-
tions.49 Furthermore, one case demonstrated that a het-
erozygous deletion of MSH6 at diagnosis was not suffi-
cient to cause a hypermutator phenotype, but the acquisi-
tion of a second hit in the WT allele at relapse was.49
Likewise, the majority of hypermutated gliomas at relapse
show defects in multiple MMR genes or loss of heterozy-
gosity.50 Thus, our work supports a model whereby hap-
loinsufficiency of MSH6 results in TGN tolerance and
resistance directly rather than by generation of secondary
mutations. However, it does not rule out the possibility
that haploinsufficiency, along with other defects in the
MMR pathway, may result in a mutator phenotype. 
Overall, it has become increasingly evident that the
genetic and epigenetic landscape of cancer cells is vital to
the overall effectiveness of treatment. These studies illus-
trate yet another example of a mutation/deletion found at
relapse that directly influences the response to a therapeu-
tic agent that is currently heavily relied on. Continuous
efforts to elucidate the potential functions and mecha-
nisms of genes found mutated at relapse will help lead us
to novel treatment strategies. 
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